An Efficacy and Safety Study for Tapentadol Extended Release (JNS024ER) in Chronic Pain Participants
10 maj 2013 uppdaterad av: Janssen Pharmaceutical K.K.
Phase II Study of JNS024ER in Japanese Subjects With Chronic Pain Due to Osteoarthritis of the Knee or Low Back Pain
The purpose of this study is to evaluate the efficacy, safety and to explore the pharmacokinetics (how drugs are absorbed in the body, how they are distributed within the body and how they are removed from the body over time) of tapentadol hydrochloride extended release (ER) tablets in Japanese participants with moderate to severe chronic pain due to osteoarthritis (disorder in which the joints become painful and stiff) of knee or low back pain.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a randomized (study drug assigned by chance), multi-center (when more than one hospital or medical school team works on a medical research study), double-blind (neither physician nor participant knows the name of the assigned drug), placebo-control (participants are randomly assigned to a test treatment or to an identical-appearing treatment that does not contain the test drug), parallel-group (each group of participants will be treated at the same time) comparison study in participants with chronic pain due to osteoarthritis of knee or low back pain.
The study duration will be of 14 weeks, which consists of a screening period of 1 week during which the participants will be evaluated for study eligibility, a treatment period of 12 weeks and a follow-up period of 1 week.
The treatment period will consist of titration period (from the initiation of the study treatment to determination of the individual's maintenance dose) and maintenance period (from completion of the titration period to the completion of the treatment period).
An optimal dose (maintenance dose) will be determined for each participant during the titration period and the treatment will be continued at the maintenance dose to assess the efficacy and safety.
Tapentadol hydrochloride ER tablets 25 to 250 milligram or placebo will be administered orally twice daily.
Efficacy and safety of the participants will primarily be evaluated by change from baseline in average pain intensity score based on 11-point Numerical Rating Scale (NRS) and Clinical Opiate Withdrawal Scale (COWS), respectively.
Participants' safety will be monitored throughout the study.
Studietyp
Interventionell
Inskrivning (Faktisk)
91
Fas
- Fas 2
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
-
Aichi, Japan
-
Amagasaki, Japan
-
Chiba, Japan
-
Chiba N/A, Japan
-
Chikushi, Japan
-
Edogawa, Japan
-
Fukuoka, Japan
-
Fukushima, Japan
-
Hiratsuka, Japan
-
Kawasaki, Japan
-
Koto, Japan
-
Matsudo, Japan
-
Meguro, Japan
-
Minato-Ku, Japan
-
Niigata, Japan
-
Niigata N/A, Japan
-
Osaka, Japan
-
Sagamihara, Japan
-
Shibuya, Japan
-
Shinjuku-Ku, Japan
-
Toshima-Ku, Japan
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
20 år och äldre (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Participants with chronic pain due to osteoarthritis of knee or low back pain continuing for at least 12 weeks before informed consent
- Participants who did not achieve adequate analgesia (pain control) with routine treatment with an oral non-opioid analgesic (drug used to control pain) at its usual upper-limit dose or at an adequate fixed dose for at least 14 consecutive days during the 12 weeks before informed consent
- Participants who have not experienced treatment with conventional opioids, except for short term use of opioid analgesics for treatment of post-operative acute pain more than 30 days before consent or temporary use of codeine phosphate or dihydrocodeine phosphate for purposes other than pain relief (e.g. for antitussive) more than 2 days before informed consent
- Participants with average pain intensity score of greater than or equal to 5 on an 11-point Numerical Rating Scale (NRS) during 48 hours before informed consent and are considered requiring opioid treatment by the Investigator
- Participants who are able to visit the medical institutions throughout the study period
Exclusion Criteria:
- Participants who are taking a monoamine oxidase inhibitor within 14 days before informed consent
- Participants with current or a history of epilepsy or seizure disorders
- Participants suspected with intracranial hypertension (e.g. traumatic encephalopathy)
- Participants with uncontrolled or clinically significant arrhythmia (irregular heart rate)
- Participants with moderate to severe liver dysfunction or severe renal dysfunction
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Placebo
|
Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks.
Dose will be adjusted as per Investigator's discretion.
|
|
Experimentell: Tapentadol Hydrochloride
|
Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks.
Dose will be adjusted as per Investigator's discretion.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change From Baseline in 11-point Numerical Rating Scale (NRS) at Week 12
Tidsram: Baseline, Week 12
|
Participants were asked to assess the average pain intensity on a 11-point NRS ranging from 0 (no pain) to 10 (maximum pain imaginable) by selecting a number applicable to their pain on the scale.
The mean pain intensity during the past 74 hours (3 days) was evaluated at Baseline and the mean pain intensity during the past 12 hours was evaluated at subsequent study visits.
|
Baseline, Week 12
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change From Baseline in 11-point Numerical Rating Scale (NRS)
Tidsram: Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
|
Participants were asked to assess the average pain intensity on a 11-point NRS ranging from 0 (no pain) to 10 (maximum pain imaginable) by selecting a number applicable to their pain on the scale.
The mean pain intensity during the past 74 hours (3 days) was evaluated at Baseline and the mean pain intensity during the past 12 hours was evaluated at subsequent study visits.
|
Baseline, Week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
|
|
Percentage of Participants With Response Based on 11-point Numerical Rating Scale (NRS)
Tidsram: Week 12
|
Percentage of participants with improvement in mean NRS score by greater than or equal to 30 percent or 50 percent in the last week from Baseline were considered as responders.
Participants were asked to assess the average pain intensity on a 11-point NRS ranging from 0 (no pain) to 10 (maximum pain imaginable) by selecting a number applicable to their pain on the scale.
|
Week 12
|
|
Number of Participants With Categorical Scores on Patient's Global Impression of Change (PGIC) Scale
Tidsram: Week 8, Week 12
|
The PGIC is a 7-point scale that requires the participants to assess how much their illness has improved or worsened relative to a Baseline state at the beginning of the intervention.
The response options are 1 = very much improved, 2 = much improved, 3 = minimally improve, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.
|
Week 8, Week 12
|
|
Number of Participants With Response Based on Physician's Global Assessment Scale
Tidsram: Week 8, Week 12
|
Physician's Global Assessment Scale assesses the therapeutic efficacy (effectiveness) of the study drug for pain control on a 2-point scale of "effective" and "not effective".
|
Week 8, Week 12
|
|
Number of Participants With Presence of Pain Based on Brief Pain Inventory-Short Form (BPI-sf) Scale
Tidsram: Baseline, Week 12
|
BPI-sf is a self-evaluated pain assessment form consisting of 15 items (item 1 - presence of pain, item 2 - pain location, items 3 to 6 - pain severity, item 7 - status of pain treatment, item 8 - efficacy of pain treatment, and items 9a to 9g - interference of pain with daily life).
Item 1 for presence of pain assesses the question: "Do you have any pain today other than everyday kinds of pain?" on a 2-point scale of "yes" or "no".
|
Baseline, Week 12
|
|
Number of Participants With 50 Percent Pain Relief Based on Brief Pain Inventory-Short Form (BPI-sf) Scale
Tidsram: Baseline, Week 12
|
BPI-sf is a self-evaluated pain assessment form consisting of 15 items (item 1 - presence of pain, item 2 - pain location, items 3 to 6 - pain severity, item 7 - status of pain treatment, item 8 - efficacy of pain treatment, and items 9a to 9g - interference of pain with daily life).
Item 8 for efficacy of pain treatment assesses number of participants with at least 50 percent pain relief during the last 24 hours on a scale ranging from 0 percent (no relief) to 100 percent (complete relief).
|
Baseline, Week 12
|
|
Change From Baseline in Brief Pain Inventory-Short Form (BPI-sf) Total Score at Week 12
Tidsram: Baseline, Week 12
|
BPI-sf consists of 15 items (item 1 - presence of pain, item 2 - pain location, items 3 to 6 - pain severity, item 7 - status of pain treatment, item 8 - efficacy of pain treatment, and items 9a to 9g - interference of pain with daily life).
Total score is defined as the mean scores from items 3, 4, 5, 6 and 9 recorded on an 11-point scale where 0 = no pain and 10 = pain as bad as you can imagine.
Negative change indicates an improvement in pain.
|
Baseline, Week 12
|
|
Change From Baseline in Sleep Latency Based on Sleep Questionnaire at Week 12
Tidsram: Baseline, Week 12
|
Sleep Latency was addressed by the question: "How long after bedtime/lights out did you fall asleep last night?"
and the change from Baseline in sleep latency was reported.
Decrease in time indicated improvement.
|
Baseline, Week 12
|
|
Change From Baseline in Time Slept Based on Sleep Questionnaire at Week 12
Tidsram: Baseline, Week 12
|
Time slept was addressed by the question: "How long did you sleep last night?"
and the change from Baseline in time slept was reported.
|
Baseline, Week 12
|
|
Number of Participants With Awakenings Based on Sleep Questionnaire
Tidsram: Baseline, Week 12
|
Number of awakenings was addressed by the question: "How many times did you wake up during the night?''
and lesser number signified better sleep.
|
Baseline, Week 12
|
|
Number of Participants With Response Based on Overall Quality of Sleep Questionnaire
Tidsram: Baseline, Week 12
|
Overall quality of sleep was addressed by the question: "Please rate the overall quality of your sleep last night" and participants could choose one of the following options: excellent, good, fair or poor.
|
Baseline, Week 12
|
|
Change From Baseline in Short Form-36 Health Survey Version 2 (SF-36v2) Scores at Week 12
Tidsram: Baseline, Week 12
|
SF-36v2 is 36-item form related to 8 health concepts (physical functioning, role physical, role emotional, general health, social functioning, bodily pain, vitality, mental health) and 2 summary scores (physical and mental component summary).
Physical functioning, role physical and bodily pain contribute to physical component; role emotional, social functioning and mental health contribute to mental component; and social functioning, vitality, and general health contribute to both.
All scores are based on a scale from 0 to 100, with higher scores defining more favorable health state.
|
Baseline, Week 12
|
|
Change From Baseline in Western Ontario MacMaster Questionnaire (WOMAC) Global Score at Week 12
Tidsram: Baseline, Week 12
|
WOMAC is a self administered 24-item questionnaire used to evaluate participants with osteoarthritis of the knee.
It consists of 3 subscales: pain (5 items), joint stiffness (2 items), and physical function (17 items).
Each item is assessed on a 5-point scale from 0 to 4. The global score assesses pain, disability and joint stiffness and ranges from 0 to 96.
Higher scores indicate that a symptom is bothersome and physically disabling.
|
Baseline, Week 12
|
|
Change From Baseline in Roland Morris Disability Questionnaire (RDQ) Score at Week 12
Tidsram: Baseline, Week 12
|
RDQ scale is used to assess the impact of low back pain on daily activities by participants.
The scale consists of 24 item questionnaire with options as "Yes"/"No" where "Yes" is counted as 1 point.
The total score ranged from 0 to 24, with higher scores indicating greater disability.
|
Baseline, Week 12
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Number of Participants With Response Based on Clinical Opioid Withdrawal Symptoms Questionnaire (COWS)
Tidsram: Week 12
|
COWS is an 11-item questionnaire for clinical assessment of withdrawal symptoms.
Total score is calculated by adding the scores of all the 11-items.
The severity of withdrawal symptoms is categorized using values of total score as: 0-4 = no withdrawal, 5-12 = mild, 13-24 = moderate, 25-36 = moderately severe, and 37-48 = severe withdrawal.
|
Week 12
|
|
Serum Concentration of Tapentadol
Tidsram: Week 2, 4, 8, 12
|
Week 2, 4, 8, 12
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 april 2010
Primärt slutförande (Faktisk)
1 december 2010
Avslutad studie (Faktisk)
1 december 2010
Studieregistreringsdatum
Först inskickad
22 april 2010
Först inskickad som uppfyllde QC-kriterierna
13 maj 2010
Första postat (Uppskatta)
17 maj 2010
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
14 maj 2013
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
10 maj 2013
Senast verifierad
1 maj 2013
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Smärta
- Neurologiska manifestationer
- Ledsjukdomar
- Muskuloskeletala sjukdomar
- Reumatiska sjukdomar
- Artrit
- Artros
- Ryggont
- Ländryggssmärta
- Artros, knä
- Kronisk smärta
- Läkemedels fysiologiska effekter
- Adrenerga medel
- Neurotransmittormedel
- Molekylära mekanismer för farmakologisk verkan
- Depressiva medel i centrala nervsystemet
- Agenter från det perifera nervsystemet
- Analgetika
- Sensoriska systemagenter
- Analgetika, Opioid
- Narkotika
- Neurotransmittorupptagshämmare
- Membrantransportmodulatorer
- Adrenerga upptagshämmare
- Tapentadol
Andra studie-ID-nummer
- CR016999
- JNS024ER-JPN-N21 (Annan identifierare: Janssen Pharmaceutical K.K., Japan)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .